Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06058962 · ClinicalTrials.gov registry record · Phase 2
Double Blind Trial in Children With Autism Spectrum Disorder
A Phase 2 study, sponsored by Paxmedica.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT06058962 is a Phase 2 study that has completed, run by Paxmedica. The registered enrollment target is 52 participants.
The verdict
NCT06058962, a Phase 2 study, has completed, sponsored by Paxmedica.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study investigated the safe and efficacious use of suramin as a novel treatment for ASD by testing two suramin doses vs placebo
Interventions
- DRUG Suramin Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-06-01 |
| Est. Completion | 2021-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06058962
The ClinicalTrials.gov registry entry for NCT06058962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Paxmedica, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Suramin Sodium is the first listed.
NCT06058962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06058962 about?
NCT06058962 is a clinical study titled "Double Blind Trial in Children With Autism Spectrum Disorder". This study investigated the safe and efficacious use of suramin as a novel treatment for ASD by testing two suramin doses vs placebo
What is the current status of trial NCT06058962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2019-06-01. Estimated completion is 2021-03-15.
What interventions are being tested in trial NCT06058962?
The interventions under investigation include: Suramin Sodium (DRUG).
Who is sponsoring clinical trial NCT06058962?
This trial is sponsored by Paxmedica, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.